Human Multiple Myeloma Peripheral Blood Mononuclear Cells (Relapsed/Refractory)

Description

Human Multiple Myeloma Peripheral Blood Mononuclear Cells (MM PBMCs) (Relapsed/Refractory) are derived from the peripheral blood of patients diagnosed with relapsed or refractory multiple myeloma, a highly aggressive plasma cell malignancy. Cell morphology is characterized by suspended growth of round to oval-shaped cells with low adherence to plastic surface. Typical MM cells show intracytoplasmic vacuolation and enlarged nucleoli. The cells exhibit high expression of abnormal monoclonal immunoglobulins and carry key drug-resistance markers, such as Cereblon (CRBN) mutations and overexpression of peptidyl prolyl isomerase A (PPIA). These molecular alterations drive resistance to immunomodulatory drugs (e.g., lenalidomide, pomalidomide) and proteasome inhibitors, making this a clinically relevant model for studying treatment-resistant myeloma. In advanced translational studies, these samples are widely used to analyze immune cell responses, profile gene expression and blood-based biomarkers, and investigate mechanisms of relapse and drug resistance in multiple myeloma.